S-1: NovaBay Pharmaceuticals Eyes Public Offering to Bolster Eyecare and Wound Care Business

NovaBay Pharmaceuticals is seeking to raise capital through a public offering of common stock and warrants to fund its eyecare and wound care product lines, including its flagship Avenova Spray.

Summary

• NovaBay Pharmaceuticals has filed a Form S-1 registration statement for a proposed public offering.
• The offering includes shares of common stock and Series F warrants to purchase common stock, as well as pre-funded warrants to purchase common stock and accompanying Series F warrants.
• The combined public offering price for each share of common stock and a Series F warrant is to be determined.
• Each Series F warrant will have an exercise price to be determined, be exercisable immediately upon issuance, and expire five years from the issuance date.
• Pre-funded warrants are offered in lieu of common stock to purchasers whose ownership would exceed 4.99% or 9.99% of outstanding shares after the offering.
• Each pre-funded warrant is exercisable for one share of common stock and is being issued with the same Series F warrants.
• The pre-funded warrants are immediately exercisable and may be exercised until fully exercised.
• The company's common stock is listed on the NYSE American under the symbol NBY, with the last reported sale price on June 20, 2024, at $2.28 per share.
• The offering price will be determined through negotiation between NovaBay and the underwriter.
• NovaBay has granted the underwriter an option to purchase additional shares of common stock and/or Series F warrants within 45 days to cover over-allotments.
• The company intends to use the net proceeds for working capital and general corporate purposes, with a portion allocated to redeem outstanding Senior Convertible Notes.
• NovaBay is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.
• Investing in NovaBay's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is pursuing a public offering to raise capital, it also faces significant financial challenges, including operating losses and substantial doubt about its ability to continue as a going concern. The competitive landscape and regulatory risks further contribute to a cautious sentiment.

Positives

• Avenova Spray has a doctor recommended halo effect around the brand.
• A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022.
• Generating sales through a loyal subscriber base provides predictable and consistent revenue, and allows us to efficiently manage our sales and marketing spend.
• The DERMAdoctor Divestiture immediately streamlined our business by reducing our cash burn and allowing us to focus on pursuing newer and stronger growth opportunities that are better aligned with our core eyecare business.
• On June 4, 2024, the Company received notice from the NYSE American that it had accepted the Companys plan of compliance and granted a plan period through October 18, 2025.

Negatives

• There is no established public trading market for the new warrants, and the company does not expect a market to develop.
• The company has sustained operating losses for the majority of its corporate history.
• The company's operating cash flow is currently not sufficient to support its ongoing operations.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• Goodwill, intangible and other assets from our DERMAdoctor acquisition in 2021 have become fully impaired, which adversely impacted our profitability in 2023 and 2022.
• On April 18, 2024, the company received a notification from the NYSE American stating that the company is not in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
• On May 28, 2024, the company received a further notification from the NYSE American, stating that the company is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide.

Risks

• There is substantial doubt about NovaBay's ability to continue as a going concern.
• The company requires additional capital to finance its operations.
• The company's future success is largely dependent on the successful commercialization of its products, particularly Avenova Spray.
• The company faces substantial competition in the eyecare market.
• The company is dependent on third parties to manufacture, supply, and distribute its products.
• The company expects continuous revenue from sales of Avenova Spray, which is classified as a cleared medical device by the FDA, but we cannot guarantee that the FDA will continue to allow us to market and sell Avenova Spray as a cleared medical device.
• The pharmaceutical and biopharmaceutical industries are characterized by patent litigation.
• The price of the company's common stock may fluctuate substantially.
• If the company is unable to comply with the continued listing requirements of the NYSE American, including its trading price per share of its common stock increasing and satisfying the obligations set forth in the Deficiency Letter with respect to its stockholders equity being below the NYSE Americans minimum level, then its common stock will be delisted from the NYSE American.
• The 2024 reverse stock split may adversely impact the market price of the company's common stock.
• You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase in the offering.
• The Series F warrants are speculative in nature.

Future Outlook

The company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will meet its capital needs through and support its continued commercialization efforts and for working capital and general corporate purposes.

Industry Context

NovaBay operates in the competitive eyecare and wound care markets, facing competition from large companies like Allergan and Shire, as well as over-the-counter products containing hypochlorous acid.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• It mentions competitors like Allergan and Shire but does not offer a detailed analysis of NovaBay's performance relative to these companies.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The offering could provide the company with the capital needed to continue operations and commercialize its products, potentially benefiting employees and customers.
• Creditors may benefit from the company's plan to use a portion of the proceeds to redeem outstanding Senior Convertible Notes.

Next Steps

• The company will negotiate the final public offering price with the underwriter.
• The underwriter will market and sell the securities to the public.
• The company will use the net proceeds from the offering for working capital, general corporate purposes, and to redeem outstanding Senior Convertible Notes.
• The company will continue to execute its business plan and commercialize its products.

Key Dates

Keywords

public offering, common stock, warrants, Avenova, eyecare, wound care, pharmaceuticals, FDA, NYSE American, NBY